NZ513961A - Eplerenone crystalline form exhibiting enhanced dissolution rate - Google Patents

Eplerenone crystalline form exhibiting enhanced dissolution rate

Info

Publication number
NZ513961A
NZ513961A NZ513961A NZ51396100A NZ513961A NZ 513961 A NZ513961 A NZ 513961A NZ 513961 A NZ513961 A NZ 513961A NZ 51396100 A NZ51396100 A NZ 51396100A NZ 513961 A NZ513961 A NZ 513961A
Authority
NZ
New Zealand
Prior art keywords
crystalline form
dissolution rate
exhibiting enhanced
enhanced dissolution
form exhibiting
Prior art date
Application number
NZ513961A
Other languages
English (en)
Inventor
Kathleen Barton
Thomas B Borchardt
Marlon V Carlos
Subhash Desai
Leonard J Ferro
Henry T Gaud
Scott Ganser
Clay R Little
Partha S Mudipalli
Mark A Pietz
Daniel R Pilipauskas
Yuen-Lung L Sing
Glenn L Stahl
Joseph J Wieczorek
Chris Y Yan
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of NZ513961A publication Critical patent/NZ513961A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NZ513961A 1999-12-08 2000-12-04 Eplerenone crystalline form exhibiting enhanced dissolution rate NZ513961A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16969099P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08
US16955699P 1999-12-08 1999-12-08
US16960899P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US16968299P 1999-12-08 1999-12-08
PCT/US2000/032416 WO2001042272A2 (en) 1999-12-08 2000-12-04 Eplerenone crystalline form exhibiting enhanced dissolution rate

Publications (1)

Publication Number Publication Date
NZ513961A true NZ513961A (en) 2004-02-27

Family

ID=27558585

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ530028A NZ530028A (en) 1999-12-08 2000-12-04 Process for producing eplerenone crystalline form exhibiting enhanced dissolution rate
NZ513961A NZ513961A (en) 1999-12-08 2000-12-04 Eplerenone crystalline form exhibiting enhanced dissolution rate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NZ530028A NZ530028A (en) 1999-12-08 2000-12-04 Process for producing eplerenone crystalline form exhibiting enhanced dissolution rate

Country Status (18)

Country Link
EP (1) EP1177204A2 (zh)
JP (1) JP2003516414A (zh)
KR (1) KR100607923B1 (zh)
CN (2) CN1557833A (zh)
AU (1) AU784946B2 (zh)
BR (1) BR0008057A (zh)
CA (1) CA2362669A1 (zh)
CO (1) CO5280211A1 (zh)
EA (1) EA007934B1 (zh)
HK (1) HK1050536A1 (zh)
HU (1) HUP0203032A3 (zh)
IL (3) IL144764A0 (zh)
MX (1) MXPA01008056A (zh)
MY (1) MY131878A (zh)
NO (1) NO20013856L (zh)
NZ (2) NZ530028A (zh)
PE (1) PE20010917A1 (zh)
WO (1) WO2001042272A2 (zh)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003225871A1 (en) * 2002-03-20 2003-10-08 Pharmacia Corporation Storage stable eplerenone formulation
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
CA2582496A1 (en) 2007-03-20 2008-09-20 Apotex Pharmachem Inc. Improved process for the preparation and purification of eplerenone
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
WO2023204729A1 (ru) * 2022-04-19 2023-10-26 Общество с ограниченной ответственностью "Гелеспон" Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
ES2293944T3 (es) * 1996-12-11 2008-04-01 G.D. Searle Llc. Procedimiento de epoxidacion.
PT1165136E (pt) * 1999-03-05 2004-02-27 Searle Llc Terapia de combinacao de inibidores da enzima de conversao da antagonista da aldosterona epoxi-esteroidal para tratamento de doenca cardiovascular

Also Published As

Publication number Publication date
IL176511A (en) 2007-08-19
AU784946B2 (en) 2006-08-03
WO2001042272A2 (en) 2001-06-14
NO20013856L (no) 2001-10-08
CA2362669A1 (en) 2001-06-14
EA200100871A1 (ru) 2002-04-25
HUP0203032A2 (hu) 2002-12-28
PE20010917A1 (es) 2001-09-10
HUP0203032A3 (en) 2003-04-28
WO2001042272A9 (en) 2002-12-12
JP2003516414A (ja) 2003-05-13
KR20010112261A (ko) 2001-12-20
NO20013856D0 (no) 2001-08-08
AU2049201A (en) 2001-06-18
CN1377365A (zh) 2002-10-30
HK1050536A1 (en) 2003-06-27
MXPA01008056A (es) 2003-07-21
CO5280211A1 (es) 2003-05-30
CN1152886C (zh) 2004-06-09
IL144764A0 (en) 2002-06-30
MY131878A (en) 2007-09-28
IL144764A (en) 2007-08-19
NZ530028A (en) 2005-08-26
KR100607923B1 (ko) 2006-08-04
CN1557833A (zh) 2004-12-29
EA007934B1 (ru) 2007-02-27
BR0008057A (pt) 2002-04-23
WO2001042272A3 (en) 2001-11-29
EP1177204A2 (en) 2002-02-06

Similar Documents

Publication Publication Date Title
NZ513961A (en) Eplerenone crystalline form exhibiting enhanced dissolution rate
NZ503981A (en) Novel amines, pharmaceutical compositions containing these amines, and uses thereof
HUP0104718A3 (en) Micronized eplerenone compositions, process for their preparation and use thereof for the preparation of pharmaceutical compositions
HUP9803018A3 (en) Use of cyclooxygenase-2 inhibitors for producing pharmaceutical compositions suitable for the treatment and prevention of tumors, tumor-veloted disorders and cachexia
CA2325633A1 (en) Steroidal sapogenins and their derivatives for treating alzheimer's disease
IL126589A (en) 2,3-disubstituted-4-(3h)-quinazolinones, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating or preventing cerebral deficits
BG105161A (en) Benzocycloheptenes, methods for the production thereof, pharmaceutical preparations containing these compounds, and their use for producing medicaments
HUP0102732A3 (en) Substituted amids, their use for producing pharmaceutical compositions and pharmaceutical compositions containing them
CA2166332A1 (en) Antiglucocorticoid steroids for the treatment of anxiety disorders
HUP0200284A2 (en) 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders, process for their preparation and pharmaceutical compositions containing them
HU9600355D0 (en) The primary and secondary neuroprotective effect of flupirtine in neurodegenerative diseases
HUP0202736A3 (en) Substituted aromatic-ring compounds, process for producing the same, and pharmaceutical compositions containing them and use thereof
CA2370834A1 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
AU1028601A (en) Isoquinoline and quinazoline derivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity
HUP0201785A3 (en) Dihydrobenzodiazepins, process for producing them, their use and pharmaceutical compositions containing them
AU1546101A (en) Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders
HUP0101898A3 (en) Meiosis regulating steroid derivatives and use thereof for producing pharmaceutical compositions
AU2562501A (en) Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders
HUP0201508A2 (en) Granular water-dispersible agents and process for producing the same
AU2401401A (en) Migrastatin, process for producing the same and medicinal compositions
HUP9901870A3 (en) 5alfa-reductase inhibitory preparation for oral administration, process for producing the same, and use thereof
WO1998057910A3 (en) Cyclooxygenase-i selective inhibitors and the use thereof as analgesic, antiinflammatory and antiarthritic agents
HUP0000679A3 (en) Use of 2,3,4,5-tetrahydro-1h-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders
ZA981918B (en) Use of 2,3,4,5-tetrahydro-1H-3-benzazepines for the manufacture of a pharmaceutical composition for the treatment of sleep disorders

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed